NovoCure Limited (NVCR)

NovoCure Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	-192.74	-207.04	-92.53	-58.35	19.81	-7.23
Depreciation & Amortization	11.06	10.97	10.62	10.25	9.15	8.46
Share-Based Compensation	110.61	115.61	106.96	94.9	75.72	52.42
Other Operating Activities	-17.11	7.13	5.74	35.96	-5.53	-27.03
Operating Cash Flow	-88.18	-73.34	30.79	82.76	99.15	26.62
Operating Cash Flow Growth	-	-	-62.80%	-16.53%	272.46%	-
Capital Expenditures	-32.79	-27.09	-21.36	-24.17	-14.97	-10.49
Change in Investments	380.87	211.24	-118.6	-120.66	-457.88	-41.18
Investing Cash Flow	348.08	184.15	-139.96	-144.83	-472.85	-51.67
Share Issuance / Repurchase	4.42	4.42	5.22	4.55	3.37	2.47
Debt Issued / Paid	-0	-0.01	-0.03	-0.03	408.41	-0.03
Other Financing Activities	6.38	11.38	10.3	21.18	28.43	59.25
Financing Cash Flow	10.8	15.79	15.49	25.7	440.21	61.68
Exchange Rate Effect	0.03	0.13	-0.1	-0.19	0.25	0.03
Net Cash Flow	270.72	126.73	-93.78	-36.56	66.76	36.66
Free Cash Flow	-120.97	-100.43	9.43	58.59	84.18	16.14
Free Cash Flow Growth	-	-	-83.90%	-30.40%	421.72%	-
Free Cash Flow Margin	-23.01%	-19.72%	1.75%	10.95%	17.03%	4.59%
Free Cash Flow Per Share	-1.13	-0.94	0.09	0.57	0.83	0.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).